Rosiglitazone and other thiazolidinediones are thought to sensitize adipose and other tissues to insulin by activating a molecule called PPARγ. A recent study suggests that the therapeutic effect of rosiglitazone is mediated by its prevention of the phosphorylation of PPARγ.
No takes yet. Share an insight, caveat, or question.
Kahn et al. (2010) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: